Please ensure Javascript is enabled for purposes of website accessibility

European Advisory Group Backs Esperion's Cholesterol Drugs

By Todd Campbell - Jan 31, 2020 at 11:29AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The committee vote puts bempedoic acid on the path for likely approval by the European Medicines Agency.

The European Medicines Agency's (EMA) advisory group has voted in favor of approving two new cholesterol-lowering medicines developed by biopharmaceutical company Esperion Therepeutics (ESPR -4.65%). Following the positive opinion from the Committee for Medicinal Products for Human Use (CHMP), formal approval of bempedoic acid by the EMA is anticipated in April.

A man looking through binoculars.

IMAGE SOURCE: GETTY IMAGES.

Bempedoic acid reduces the production of low-density lipoprotein cholesterol (LDL-C) in the body by targeting ATP citrate lyase (ACL), an enzyme that plays an important role in fatty acid biosynthesis. 

Esperion Therapeutics is seeking approval of single tablet bempedoic acid and a combination pill comprising bempedoic acid and Zetia, a blockbuster medication that reduces absorption of cholesterol from the gastrointestinal tract. If approved, these drugs could be used alongside or as an alternative to statins, a commonly prescribed class of medications used to lower LDL-C.

CHMP's opinion on bempedoic acid was supported by positive clinical trial results. In phase 3 studies, bempedoic acid lowered LDL-C by up to 18% when used alongside statins and by up to 28% when used without statins. The bempedoic acid and Zetia combination pill lowered LDL-C by 38% compared to placebo.

These results also support the company's applications for approval of the treatments in the United States. Decisions from the Food and Drug Administration  are expected for those drugs on Feb. 21 and Feb. 26, respectively.

If they are approved, Esperion's European commercialization partner, Daiichi Sankyo, will market the drugs in Europe. In the U.S., Esperion Therapeutics will commercialize the drugs itself. 

In the U.S., 96 million people have elevated LDL-C, including 18 million people with atherosclerotic cardiovascular disease (ASCVD) who have elevated bad cholesterol levels, despite taking statins. 

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Esperion Therapeutics Stock Quote
Esperion Therapeutics
ESPR
$6.36 (-4.65%) $0.31

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
317%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/30/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.